Nasal compositions of vitamin B12

A technology for a composition and an aqueous composition, which is applied in the directions of pharmaceutical combinations, medical preparations without active ingredients, and medical preparations containing active ingredients, etc., can solve the problems of unavailability, low solubility of methylcobalamin, instability, Bioavailability has not been resolved etc.

CN103384513AActive Publication Date: 2013-11-06TROIKAA PHARMA
4 Cites 1 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
Publication Date
2013-11-06

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

Vitamin B-12 deficiency is very common among population. The main causes of B- 12 deficiency include lack of intrinsic factors and other intestinal factors (e.g. malabsorption), rare genetic disorders, and inadequate intake. The present invention relates to intranasal formulations of vitamin B derivatives such as methylcobalamin, Cyanocobalamin which provide enhanced transnasal absorption.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The present invention relates to intranasal compositions of vitamin B-12 derivatives such as methylcobalamin, cyanocobalamin and hydroxocobalamin and methods for their preparation. Background technique

[0002] Vitamin B-12 deficiency is very common in the population. Large surveys in the US and UK revealed that about 6% of people aged 60 or older are deficient in vitamin B-12. Furthermore, in developing countries such as India, this deficiency is more common, starts early in life and persists throughout life. A study of 441 middle-aged men in Pune (India) revealed that 67% had low vitamin B-12 concentrations (<150 pmol / L). Among the urban middle class, 81% had lower vitamin B-12 concentrations, and vegetarians had a 4.4-fold higher risk of developing low vitamin B-12 concentrations.

[0003] The main causes of B-12 deficiency include lack of intrinsic factor and other intestinal factors (eg, malabsorption), rare genetic disorders, and insufficie...

Examples

example 1

[0125] Element

[0126] The pH of the formulation was adjusted to 6.25 ± 0.5 and the viscosity of the formulation was found to be 1.28 CPS.

example 2

[0128] Element

[0129] The pH of the formulation was adjusted to 6.25 ± 0.5 and the viscosity of the formulation was found to be 2.3 CPS.

example 3

[0131] Element

[0132] Tetrahydrofuran polyethylene glycol ether

[0133] The pH of the formulation was adjusted to 6.25 ± 0.5 and the viscosity of the formulation was found to be 1.57 CPS.